Managing Side Effects of HER2 Targeted Therapy - Zanidatamab & Trastuzumab deruxtecan (T-DXd)

6 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
In this episode of the Oncology Brothers podcast, Drs. Rahul & Rohit Gosain wrap up their three-part CME series on HER2-positive biliary tract cancer. Joined by Dr. Rachna Shroff, they delved into the critical topic of managing adverse events associated with treatments like TDXD and Zanidatamab.

The discussion covered:
•⁠ ⁠Overview of the treatment landscape for biliary tract cancer
•⁠ ⁠Common side effects of TDXD, including interstitial lung disease, nausea, and fatigue
•⁠ ⁠Management strategies for adverse events, including dose reductions and supportive care
•⁠ ⁠Insights on Zanidatamab, its side effects, and infusion-related reactions
•⁠ ⁠The importance of biomarker testing and patient-centered care in treatment decisions

Tune in to gain valuable insights on how to improve patient quality of life while navigating the complexities of HER2-positive biliary tract cancer treatments.

Apple Podcast: https://podcasts.apple.com/us/podcast/managing-side-effects-of-her2-targeted-therapy/id1653340966?i=1000706888979
Spotify: https://open.spotify.com/episode/0mKVi6F7tDEj41CLn4OtDY?si=9hOVLywpSC6d65_CXFKgww

Follow us on social media:
•⁠ ⁠X/Twitter: https://twitter.com/oncbrothers
•⁠ ⁠Instagram: https://www.instagram.com/oncbrothers
•⁠ Website: https://oncbrothers.com/

Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
Category
Oncology
Be the first to comment

Up Next